Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Feb 5, 2024

31100_dirs_2024-02-05_0cfe019a-7242-4b47-a1c1-070cca40968d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-02-01

Reporting Person: Eydelman Mikhail (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-01 Common Stock M 1667 $21.41 Acquired 22377 Direct
2024-02-01 Common Stock S 212 $72.215 Disposed 22165 Direct
2024-02-01 Common Stock S 638 $73.165 Disposed 21527 Direct
2024-02-01 Common Stock S 343 $74.11 Disposed 21184 Direct
2024-02-01 Common Stock S 474 $75.391 Disposed 20710 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-01 Stock Option (Right to Buy) $21.41 M 1667 Disposed 2032-05-08 Common Stock (1667) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.695 to $73.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.70 to $74.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.01 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F6: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.